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Abstract 
Mena (mammalian Ena) is an actin regula-
tory protein involved in cell motility and adhe-
sion. Based on its potential role in malignant
transformation revealed in other organs, we
analyzed the Mena expression in normal sali-
vary glands (SG) and salivary tumors. Mena
expression  was  determined  in  normal  SG
(n=10) and also benign (n=20) and malignant
(n=35) lesions of SG. For the immunohisto-
chemical staining we used the anti-Mena anti-
body. All normal SG and the benign lesions (10
pleomorphic adenomas, 10 Warthin’s tumors)
were Mena negative. Salivary duct carcinomas
(n=5),  carcinomas  in  pleomorphic  adenoma
(n=5),  acinic  cell  carcinomas  (n=5),  squa-
mous cell carcinomas (n=10) and high-grade
mucoepidermoid carcinomas (n=2) were posi-
tive.  The  lymphomas  (n=5)  and  low-grade
mucoepidermoid  carcinomas  (n=1)  were
Mena negative. In one case the lymphoblastic
cells stained positive for Mena. Some of the
endothelial cells, in the peritumoral vessels,
were Mena positive. To the best of our knowl-
edge, this is the first study in the literature
about Mena expression in salivary tumors. Our
study  suggests  that  Mena  protein  seems  to
play a role in malignant transformation and its
intensity is correlated with the type and grade
of tumor and also with vascular invasion. Its
positivity in endothelial cells may suggest its
potential role in tumor angiogenesis.
Introduction
Carcinomas of salivary gland (SG) represent
3-5%  of  head  and  neck  tumors1 respectively
11% of all oropharyngeal neoplasms.2 Half of
salivary gland tumors are pleomorphic adeno-
mas.3 Malignant  tumors  are  relatively  rare.
Some of them are developing in pleomorphic
adenomas but the pathomechanism of carcino-
genesis and prognostic factors of these cases
are still under debate. However, lymph node
metastases and relapses have been reported
and therefore the outcome is not always favor-
able. The causes of relapses have been attrib-
uted to the positivity of resection margins, or
unfavorable prognostic factors such as tumor
stage, gender, age, histological grade, site and
size  of  tumor  as  well  as  status  of  regional
lymph nodes.4
Based on the tumor agresitivity and histo-
logical  aspect,  malignant  tumors  of  salivary
glands are classified in low grade (low-grade
adenocarcinoma,  basal  cell  adenocarcinoma,
acinic cell carcinoma, clear cell adenocarcino-
ma,  epithelial-myoepithelial  carcinoma,  and
cystadenocarcinoma) and high grade (salivary
duct  carcinoma,  squamous  cell  carcinoma,
adenosquamous carcinoma, oncocytic carcino-
ma, sebaceous carcinoma and undifferentiated
carcinomas) but in some tumors (mucoepider-
moid  carcinoma,  adenocarcinoma  NOS,  ade-
noid  cystic  carcinoma  and  malignant  mixed
tumors)  the  grading  system  is  still  under
debate.5 New markers and molecular analyses
are necessary to be introduced in these cases
in the daily diagnosis in order to predict prog-
nosis and capacity of metastasing.5
Recent  studies  proved  that  cell  migration
and  adhesion  is  mediated  by  the  actin
cytoskeleton and altered expression of regula-
tors of the actin cytoskeletal network can con-
tribute to metastasis.6 One protein family reg-
ulating  actin  cytoskeleton  dynamics  is  the
enabled/vasodilator stimulated phosphoprotein
(Ena/VASP) family.7 Members of this family in
vertebrates are Mena (mammalian Ena), VASP
(vasodilator  stimulated  phosphoprotein)  and
EVL (Ena/VASP-like). Ena/VASP proteins play a
crucial  role  in  cell  motility  by  antagonizing
actin filament capping. 
In  breast  and  pancreatic  carcinomas  and
also in melanomas it was observed that Mena
was up-regulated and facilitated metastasis.8,9
There  are  previously  reported  that  Mena
expression is up-regulated during malignant
transformation of colorectal tumors and cervi-
cal intraepithelial into invasive neoplasia.10,11
However,  expression  levels  of  Mena  during
carcinogenesis of salivary glands have not yet
been reported.
Therefore, we have analysed Mena expres-
sion levels in normal salivary glands and in
some  of  the  benign  and  malignant  salivary
tumors in order to determine its potential role
as biomarker for tumor progression.
Materials and Methods
Paraffin  embedded  tissues  of  65  patients
with normal salivary glands and primary sali-
vary gland tumors diagnosed in Department of
Pathology  of  Emergency  Hospital  of  Targu-
Mures, Romania, during 2005-2011 were retro-
spectively  analysed.  The  selection  process
included a randomized selection depending on
the diagnosis time. Due to small number of
cases  no  other  criterias  have  been  used.
Protein expression levels were correlated with
demographic data and clinical outcome includ-
ing  relapses.  Ethical  committee  of  our
University  granted  their  approval  for  these
techniques.  Written  informed  consent  from
patients was obtained for this study. Number
of  tumors  and  normal  tissue  with  SG  are
shown in Table 1. 
For immunohistochemical staining we used
the  monoclonal  anti-Mena  antibody,  isotype
mouse IgA, clone 21 (BD Biosciences, Sparks,
MD, USA) which recognizes all the Mena iso-
forms and do not crossreact with other mem-
bers of ENA/VASP family. Indirect streptavidin-
biotin-peroxidase system was applied in for-
malin-fixed,  paraffin-embedded  sections.  For
antigen  unmasking,  the  deparaffinized  and
rehydrated sections were pretreated in a ther-
mostatic bath at 96°C for 30 min in 10 mM cit-
rat buffer, pH 6. It was followed by endogenous
peroxidase blocking and incubation with pri-
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mary  and  secondary  antibody  (LabVision,
Kalamazoo,  MI,  USA)  at  room  temperature.
HRP  Polymer  detection  kit  (Ultravision  LP
Large Volume, LabVision) served as visualisa-
tion system. The development was performed
with  substrate-chromogen  solution  3,3'
Diamino Dihidrochlorid Benzidine (DAB) for
3-5 min. The nuclei were counterstained with
Mayer`s Hematoxylin. We should mention that
for each staining batch avidin-biotin blocking
of non-specific background staining was per-
formed  in  order  to  reduce  the  non-specific
background staining.11,12
The Mena immunostaining was scored in
the cytoplasm of tumor cells according to the
following criteria: score 0, no staining; score
1+, weak diffuse cytoplasmic staining in <10%
of cells; score 2+, moderate cytoplasmic stain-
ing in 10% to 70% of cells a; score 3+, strong
cytoplasmic staining in >70% of the cells, with
or without juxtamembrane reinforce. Smooth
muscle cells were used as an internal positive
control.13 For external control we used human
cerebellum as positive and spleen as negative
control.14,15
The  digital  pictures  were  realized  with
Nikon  800E  microscope  and  were  processed
using ImageJ (NIH) software. Mena intensity
was statistically correlated with following clin-
icopathological parameters: patients sex and
age, tumor type, tumor stage, grade of malig-
nancy, lymph node metastases, rate of recur-
rence and angiolymphatic invasion. For statis-
tical analysis, we used the statistics program
GraphPad InStat 3. We used the t-test, c2-test
and the contingency tables, Fischer’s test and
One way Anova test. A P value <0.05, with a
95% confidence interval, was considered sig-
nificant. 
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Table  1.  Distribution  of  patients  in  the
study.
Type of tissue No. of 
patients
Normal salivary glands 10
Benign tumors 20
Pleomorphic adenoma 10
Warthin’s tumor 10
Malignant tumors 35
Salivary duct carcinoma  5
Carcinoma in pleomorphic adenoma 5
Acinic cell carcinoma 5
Squamous cell carcinoma 10
Mucoepidermoid carcinoma 5
Lymphoma  5
Table 2. Clinical parameters of patients. 
Type of tissue Age Male/female
median/interquartile (ratio)
range (years) 
Normal salivary glands 55.62 (46-70) 1/1
Benign tumors 60.12 (44-76)  4/1
Pleomorphic adenoma 51.33 (44-64) 1/3
Warthin’s tumor 73.01 (70-76) 10/0
Malignant tumors 61.36 (35-85)  1/1
Salivary duct carcinoma 71.23 (70-73) 2/1
Carcinoma in pleomorphic adenoma  62.34 (55-65) 1/1
Acinic cell carcinoma 51.45 (37-65) 1/3
Squamous cell carcinoma 74.66 (62-85) 3/1
Mucoepidermoid carcinoma 46.52 (35-63) 1/3
Lymphoma  54.66 (41-62) 1/2
Figure 1. Lack of Mena expression in benign tumors of salivary glands. The arrows indi-
cate extracellular apical positivity. 
Figure 2. Lack of Mena expression in diffuse large B-cell lymphomas (DLBCL), with pos-
itivity of lymphoblast cells.[European Journal of Histochemistry 2012; 56:e8] [page 41]
Results 
Patients’ characteristics
The demographic distribution of patients is
presented in Table 2. We found a female pre-
dominance  in  pleomorphic  adenomas
(P=0.03), acinic cell carcinomas (P=0.04) and
mucoepidermoid carcinomas (P=0.01). In case
of  malignant  tumors,  the  median  age  was
61.36 years (range between 35-85 years). All
Wharthin  tumors  were  diagnosed  in  males
older than 70 years. No statistical differences
between age of patients with benign or malig-
nant tumors were observed (P=0.65). Only one
patient with carcinoma in pleomorphic adeno-
ma presented recurrences, one year after sur-
gical interventions. All patients survived one
year after surgical intervention.
Particularities of Mena staining
As already mentioned, the quantification of
Mena  intensity  was  performed  in  the  cyto-
plasm of the tumor cells, independently by the
membranar aspect.
No  differences  between  sex  or  age  of
patients and Mena intensity was observed in
both  benign  and  malignant  tumors  of  SG
(P=0.0003).  In  normal  salivary  gland  tissue,
Mena was not detectable. All pleomorphic ade-
nomas were also Mena negative (Figure 1).
Regarding Warthin’s tumors, the tumor cells
were Mena negative but in one case a weak
positivity  was  observed  extracellular,  on  the
surface  of  the  apical  membrane  (Figure  1).
This case was also considered negative and the
strange positivity cannot be explained at the
moment. It may be a positivity of the tumor
secretion but future studies should elucidate
this aspect. Regarding the intensity of Mena
staining  in  diffuse  large  B-cell  lymphomas,
four out of five lymphomas were Mena nega-
tive. However, in one case lymphoblastic cells
were Mena positive (Figure 2).
We observed that Mena staining intensity
was 1+ in two cases and 2+ in three cases of
acinic cell carcinoma. Furthermore, in all sali-
vary duct carcinomas and carcinomas in pleo-
morphic  adenomas  the  intensity  of  Mena
staining was 3+ regardless whether the cases
were with or without relapses (Figure 3, Table
3).  In squamous cell carcinomas and mucoepi-
dermoid  carcinomas  we  observed  a  positive
correlation between tumor grade and intensity
of Mena staining. In low grade squamous cell
carcinomas the intensity of Mena staining was
2+ and in high grade squamous cell carcino-
mas  Mena  intensity  was  3+  (Figure  4).  In
mucoepidermoid carcinomas, no or weak posi-
tivity was revealed by low- and intermediate-
grade  carcinomas  but  the  strong  intensity
(3+) was observed in high-grade types (Figure
5, Table 3).
In case of salivary duct carcinomas, inde-
pendently by the tumor type, the mena intensi-
ty was not correlated with other parameters
than tumor grade and vascular invasion, being
2+ or 3+ in all high-grade carcinomas and in
cases with vascular invasion. In acinic cell car-
cinomas,  for  example,  although  it  is  a  low-
grade tumor, all 3 cases with 2+ intensity pre-
sented vascular invasion but no invasion was
identified in the two cases with 1+ intensity.
No correlation have been observed between
Mena  intensity  and  other  clinicopathologic
parameters  as:  patients`sex  and  age,  tumor
stage or lymph node metastases. Although the
Mena intensity was increased in the invasion
front, the small number of cases and minimal
differences between intensity inside of tumor
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Figure 3. Mena protein positivity in some salivary carcinomas. In the carcinoma devel-
oped in pleomorphic adenoma, Mena staining lack in the areas of adenoma.
Table 3. Mena protein expression in salivary gland carcinomas correlated with grade of malignancy. 
No. of cases Mena score
0 1+ 2+ 3+    
Salivary duct carcinoma:  5 ---5
Carcinoma in pleomorphic adenoma:  5  ---5
Acinic cell carcinoma:  5 -23-
Squamous cell carcinoma:  10
low-grade:    4 --4-
high-grade:   6 ---6
Mucoepidermoid carcinoma: 5
low-grade:    1 1- --
intermediate-grade:   2 11 --
high-grade:    2 ---2[page 42] [European Journal of Histochemistry 2012; 56:e8]
and invasion front do not allowed us to emite a
pertinent sentence about this aspect. 
In  some  cases,  we  observed  that  some
endothelial  cells  in  the  peritumoral  vessels
were Mena positive (Figure 6).
Discussion
Malignant  tumors  of  salivary  glands  (SG)
have a low incidence and can appear de novo
or  through  malignant  transformation  of
benign tumors. However, salivary duct carcino-
mas, invasive carcinomas ex pleomorphic ade-
nomas and also high grade squamous carcino-
mas are extremely agressive tumors, with high
rate  of  recurrences  and  distant  metastasis.4
Pleomorphic adenomas recur in 3.4% of cases
in 5 years and 6.8% in 10 years. Furthermore,
the risk for malignant transformation is high-
er  in  young  patients.16 Variable  outcome  in
individual  cases  was  observed.  To  predict
patients’  outcome  different  grading  systems
were proposed but they are still under debate,
especially  for  mucoepidermoid  carcinoma,
adenoid  cystic  carcinoma  and  malignant
mixed tumors.5
Our study suggests that the actin-binding
protein Mena, a member of Ena/VASP family
may play a role in tumorigenesis of SG. We
observed a positive correlation between Mena
expression levels and tumor grade indicating
that Mena might serve as a biomarker, espe-
cially in those cases in which criteria for grad-
ing system are not very well defined. Its inten-
sity  was  also  positively  correlated  with  the
grade of cervical intraepithelial neoplasia and
risk  of  metastasis  in  breast  and  pancreatic
tumors.8,9,13 It  was  shown  previously  that  in
colon lesions Mena marked only some adeno-
mas with dysplasia and all carcinomas, further
supporting the idea that Mena expression lev-
els could be used as a prognostic marker.1
In salivary glands, lack of Mena expression
in normal tissue and benign tumors and its
increase  in  intensity  in  carcinomas  also
reported  for  other  epithelial  neoplasms  sug-
gests  that  reorganization  of  the  actin
cytoskeleton  is  activated  during  malignant
transformation.8,10 In tumors of several organs
Mena staining localizes in the cytoplasma of
tumor cells.8,10,13Interestingly, we observed that
in malignant salivary tumors both cytoplasma
and the plasma membrane, an important intra-
cellular site of Mena function, were labelled.  
Lack of positivity in benign tumors and low
or moderate Mena intensity (1+, 2+) in acinic
cell carcinomas, low grade squamous carcino-
mas and low- or intermediate-grade mucoepi-
dermoid carcinoma, which are considered to
have  a  better  prognosis,  suggest  that  Mena
could be a prognostic factor in salivary tumors.
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Figure 4. High intensity of Mena protein in high grade squamous cell carcinoma in con-
trast with intermediar positivity in low grade variant.
Figure 5. High intensity of Mena protein in high grade mucoepidermoid carcinoma in
contrast with lack of expression in low grade variant.
Figure 6. Endothelial cells marked by Mena in salivary squamous cell carcinoma carcino-
ma and diffuse Large B-cell lymphoma.[European Journal of Histochemistry 2012; 56:e8] [page 43]
Its intensity may also indicate the probability
of presence or absence of vascular invasion.
Based on previous statement, carcinomas in
pleomorphic adenomas, salivary duct carcino-
mas and high grade squamous cell carcinomas
remain agressive salivary tumors. We should
mention  again  that  Mena  could  help  the
pathologist in correct staging of mucoepider-
moid carcinoma and proper predicting of prog-
nosis.
Our  suggestions  are  in  accordance  with
other recent studies which revealed that multi-
photon-based intravital imaging of Mena pro-
tein has demonstrated that it may be used to
develop prognostic tests which can be useful
for  patients  with  different  malignancies.17-19
This sentence is based on observation that an
alternative splicing of Mena produces two pro-
tein isoforms with distinct finctions: MenaINV
(previously  called  Mena+++)  and  Mena11a,17
both of them being part of a marker of metasta-
tic  risk  called  Tumor  Micro-Environment  of
Metastasis  (TMEM)  but  having  opposite
effects.18 One hand, MenaINV is present only in
invasive tumor cells and is not a component of
other members of ENA/VASP family. In case of
breast cancer, it can promote the discohesivity
of  tumor  cells,  increases  their  motility,
transendothelial  migration  and  intravastion,
favorizing the metastatic process.18,19 On the
other hand, Mena11a seems to be specifical for
primary epithelial cancer cells but is not coun-
terpart of mesenchymal cells or invasive tumor
cells.17 It  contribute  to  supression  of  the
paracrine-mediated  invasion  and  intravasa-
tion of the breast cancer cells.19 These studies
proved that the steps of metastasation in case
of breast cancer depend on the predominated
Mena isoform.18,19
At the moment, the immunohistochemical
methods  can  identify  the  combined  form  of
Mena. In the future, new antibodies with the
splicing variant of Mena could be useful to pre-
dict prognosis but also to develop new drugs
which  can  inhibite  MenaINV  and  prevent
metastatic disease in case of breast cancer but
also in other malignant tumors. 
The lack of Mena expression in lymphomas
suggests  that  the  actin  filaments  are  not
implied  in  genesis  of  lymphomas  but  Mena
positivity in lymphoblast cells proves that actin
reorganization or phosphorylation could influ-
ences  outcome  of  lymphomas.  No  studies
about Mena aspects in lymphomas were pub-
lished yet.
Furthermore, we observed Mena expression
in  some  of  the  stroma  endothelial  cells.
Therefore,  it  is  tempting  to  speculate  that
Mena might play a role in tumor angiogenesis.
Previous studies revealed that in the endothe-
lium,  the  Ena/VASP  family  functions  during
sealing of cell-cell contacts and  hence regula-
tion of endothelial permeability.20-23 Ena/VASP
proteins have also been implicated in endothe-
lial  reorganization  during  capillary  morpho-
genesis.24 In support of a role for Ena/VASP
proteins in tumor angiogenesis we observed a
significant correlation between Mena intensi-
ty and presence of vascular invasion and also
with microvascular density in colorectal carci-
noma.10
Further  studies  on  a  higher  number  of
patients with benign and malignant salivary
tumors,  which  include  many  categories  of
tumors, will be required to further evaluate the
suitability of Ena/VASP proteins as prognostic
or predictive biomarkers.
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